These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 8494993

  • 1. Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma.
    Kalmanti M, Karamolengou K, Dimitriou H, Tosca A, Vlachonikolis I, Peraki M, Georgoulias V, Kalmantis T.
    Int J Hematol; 1993 Apr; 57(2):147-52. PubMed ID: 8494993
    [Abstract] [Full Text] [Related]

  • 2. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y, Tsurumi H, Sawada M, Yamada T, Hara T, Fukuno K, Goto H, Moriwaki H.
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
    Filella X, Blade J, Guillermo AL, Molina R, Rozman C, Ballesta AM.
    Cancer Detect Prev; 1996 Aug; 20(1):52-6. PubMed ID: 8907203
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?
    Dincaslan HU, Yavuz G, Unal E, Tacyildiz N, Ikinciogullari A, Dogu F, Guloglu D, Yuksek N, Ertem U.
    Pediatr Hematol Oncol; 2010 Oct; 27(7):503-16. PubMed ID: 20677920
    [Abstract] [Full Text] [Related]

  • 10. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
    Remberger M, Ringdén O.
    Transplantation; 1995 Dec 15; 60(11):1293-9. PubMed ID: 8525524
    [Abstract] [Full Text] [Related]

  • 11. Tumor necrosis factor in children with malignancies.
    Saarinen UM, Koskelo EK, Teppo AM, Siimes MA.
    Cancer Res; 1990 Feb 01; 50(3):592-5. PubMed ID: 2297700
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies.
    Nakase K, Tsuji K, Tamaki S, Tanigawa M, Ikeda T, Miyanishi E, Shiku H.
    Cancer Detect Prev; 2005 Feb 01; 29(3):256-9. PubMed ID: 15899555
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W, Chyczewska E, Kovalchuk O, Tałałaj J, Izycki T, Panek B.
    Rocz Akad Med Bialymst; 2004 Feb 01; 49():246-51. PubMed ID: 15631351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.